Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
15 participants
OBSERVATIONAL
2020-08-14
2022-01-26
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Hemostasis in COVID-19: an Adaptive Clinical Trial
NCT04466670
Study of Coagulation Profile and Role of Heparin Like Effect in Patients With COVID-19
NCT04668404
Pro-thrombotic Status in Patients with SARS-Cov-2 Infection
NCT04343053
Clinical Efficacy of Heparin and Tocilizumab in Patients With Severe COVID-19 Infection
NCT04600141
Is Bio-adrenomedullin (Bio-ADM) a Prognostic Factor in Patients With COVID-19 Treated in the ICU?
NCT04813939
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
This single-center, prospective, observational pilot study will characterize changes in the coagulation status of patients with COVID-19 infection during their hospital stay using the Quantra QPlus System.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Subjects admitted to floor
COVID-19 patients admitted to the floor as initial place of hospitalization
Quantra System
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Subjects admitted or transferred to ICU
COVID-19 patients admitted to the ICU as initial place of hospitalization or transferred to ICU from floor
Quantra System
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Quantra System
Diagnostic device to monitor coagulation properties of a whole blood sample at the point-of-care.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Subject has a diagnosis of COVID-19 and has been admitted to the hospital
* Subject has one or more risk factors for a poor outcome with COVID-10 disease: advanced age (\>=60 years), morbid obesity, diabetes, COPD, CAD
* Subject, or subject's legally authorized representative is willing and agrees to provide informed consent.
Exclusion Criteria
* Subject is pregnant
* Subject is incarcerated.
* Subject, or subject's legally authorized representative is unable or unwilling to provide informed consent.
* Subject is affected by a condition that, in the opinion of the treatment team, may pose additional risks.
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
HemoSonics LLC
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Texas Tech University Health Sciences Center El Paso
El Paso, Texas, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
HEMCS-035
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.